Pharma News

Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.

Currax™ Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.

Monday, September 30, 2019

Currax Pharmaceuticals LLC a specialty biopharmaceutical company with both Branded and generic business units announced today the acquisition of Nalpropion Pharmaceuticals As a result of this acquisition Currax now owns the worldwide rights to CONTRA...

Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites

Monday, September 30, 2019

Clover Biopharmaceuticals a biotechnology company focused on developing novel and transformative biologic therapies today announced that the first patient was dosed in another Phase I trial of SCB an investigational fullyhuman TRAILTrimer fusion prot...

Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

Friday, September 27, 2019

Catabasis Pharmaceuticals Inc a clinicalstage biopharmaceutical company and the Jain Foundation a nonprofit foundation whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency announced a preclinical research collaboration...

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

Friday, September 27, 2019

Moderna Inc a clinicalstage biotechnology company pioneering messenger RNA mRNA therapeutics and vaccines to create a new generation of transformative medicines for patients today announced a multiyear research collaboration with Harvard University w...

NeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders

Thursday, September 26, 2019

NeuCyte Inc an innovative biotech company focused on developing novel treatments for neurological disorders today announced that it has entered into an exclusive license agreement with Trillium Therapeutics to advance an undisclosed preclinical compo...

Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)

Thursday, September 26, 2019

Blade Therapeutics a biopharmaceutical company advancing novel antifibrotic therapies today announced the acquisition of ATXCo Inc including its core asset PAT a Phase I ready autotaxin inhibitor for patients with fibrotic diseases

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

Wednesday, September 25, 2019

The Ivy Brain Tumor Center at Barrow Neurological Institute today announced a new collaboration with QED Therapeutics Inc a subsidiary of BridgeBio Pharma Inc NasdaqBBIO to investigate the FGFR tyrosine kinase inhibitor infigratinib for the treatment...

ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

Wednesday, September 25, 2019

IMMUNOPRECISE ANTIBODIES LTD an industry leader in the discovery of novel therapeutic antibodies announces that Talem Therapeutics its whollyowned subsidiary has entered into an LOI to form a Joint Venture as it partners in the continued development...

Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

Tuesday, September 24, 2019

Anchiano Therapeutics Ltd a pivotalstage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer today reported that Anchiano Therapeutics Inc the Companys US subsidiary has entered into an exclusive w...

I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab)

Tuesday, September 24, 2019

IMab Biopharma IMab a China and USbased clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential firstinclass and bestinclass biologics in immunooncology and autoimmune diseases today announced that...

Latest Issue
Get instant
access to our latest e-book